AVIR Atea Pharmaceuticals Inc
Price (delayed)
$4.03
Market cap
$340.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.1
Enterprise value
$98.85M
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding
Highlights
The debt has declined by 27% year-on-year and by 9% since the previous quarter
Atea Pharmaceuticals's quick ratio has decreased by 50% YoY but it has increased by 44% QoQ
Atea Pharmaceuticals's net income has plunged by 66% YoY and by 8% from the previous quarter
Atea Pharmaceuticals's EPS has shrunk by 64% YoY and by 7% QoQ
Key stats
What are the main financial stats of AVIR
Market
Valuations
Earnings
Shares outstanding
84.42M
Market cap
$340.22M
Enterprise value
$98.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$174.95M
EBITDA
-$174.54M
Free cash flow
-$121.49M
Per share
Balance sheet
Liquidity
EPS
-$2.1
Free cash flow per share
-$1.44
Book value per share
$5.66
Revenue per share
$0
TBVPS
$6.06
Total assets
$510.38M
Total liabilities
$33.91M
Debt
$2.03M
Equity
$476.47M
Working capital
$479.75M
Debt to equity
0
Current ratio
19.02
Quick ratio
18.87
Net debt/EBITDA
1.38
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-31.1%
Return on equity
-33.2%
Return on invested capital
-47.6%
Return on capital employed
-36.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVIR stock price
How has the Atea Pharmaceuticals stock price performed over time
Intraday
0.25%
1 week
9.81%
1 month
9.51%
1 year
26.73%
YTD
32.13%
QTD
21.75%
Financial performance
How have Atea Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$204.08M
Net income
-$176M
Gross margin
N/A
Net margin
N/A
Atea Pharmaceuticals's net income has plunged by 66% YoY and by 8% from the previous quarter
The operating income has shrunk by 53% YoY and by 6% QoQ
Growth
What is Atea Pharmaceuticals's growth rate over time
Valuation
What is Atea Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atea Pharmaceuticals's EPS has shrunk by 64% YoY and by 7% QoQ
AVIR's P/B is 42% higher than its last 4 quarters average of 0.5
The company's equity fell by 21% YoY and by 6% QoQ
Efficiency
How efficient is Atea Pharmaceuticals business performance
The company's return on equity has shrunk by 98% YoY and by 14% QoQ
AVIR's return on invested capital has dropped by 96% year-on-year and by 19% since the previous quarter
The ROA has shrunk by 92% YoY and by 13% QoQ
Dividends
What is AVIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVIR.
Financial health
How did Atea Pharmaceuticals financials performed over time
The current ratio has dropped by 50% year-on-year but it rose by 43% since the previous quarter
Atea Pharmaceuticals's quick ratio has decreased by 50% YoY but it has increased by 44% QoQ
The debt is 100% smaller than the equity
The debt has declined by 27% year-on-year and by 9% since the previous quarter
The company's equity fell by 21% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.